Thirty Madison Raises $47M in Series B Financing From Polaris Partners, Johnson & Johnson Innovation
Thirty Madison, a leading digital health company reinventing the patient experience for the estimated 133 million Americans living with chronic conditions, announced a $47 million Series B round led by Polaris Partners. New investor Johnson & Johnson Innovation – JJDC, Inc. (JJDC) also participated in the funding, along with existing investors Maveron and Northzone. Thirty Madison has raised a total of $70 million to date.
Thirty Madison, founded in 2017 by Steven Gutentag and Demetri Karagas, was launched with a single vision: To build the highest quality care experiences for treating chronic health conditions. Through Thirty Madison’s three portfolio brands — Keeps, Cove, and Evens — patients can easily access specialist-level care combined with the convenience of telemedicine and treatment delivery. Each platform offers individualized health care to patients suffering from hair loss (Keeps), migraine (Cove), and acid reflux (Evens) at an affordable cost. With virtual doctor visits and a wide range of therapeutic treatments, tools, and educational content individually tailored to the needs of patients, these groundbreaking brands are reimagining and improving the way chronic conditions are treated.
Recommended AI News: WNS Wins Strategic Finance & Accounting Contract With EV Cargo
With this new round of investment, Thirty Madison plans to further innovate in the digital healthcare space, specifically making the overall experience more enjoyable for those with chronic conditions. Steven Gutentag, co-founder and CEO of Thirty Madison notes, “We are excited to have JJDC as an investor, given Johnson & Johnson’s leadership across healthcare and consumer health, and their commitment to putting consumers and patients first.”
Recommended AI News: Resolve Welcomes Scale-Up Veteran David Moran to Its Board of Directors
Amy Schulman, managing partner at Polaris Partners, will also join Thirty Madison’s Board of Directors. “Over 59% of Americans suffer from at least one chronic condition, but few resources exist to help them connect the dots of their care,” said Schulman. “I have spent much of my career finding and implementing solutions predicated on putting patients first, and Thirty Madison represents the type of progress in healthcare that has become even more necessary and timely during this current moment.”
Gutentag adds, “As the former president of Pfizer Consumer Healthcare, Amy has had a transformative influence on the consumer healthcare space, and we are thrilled to have her leadership and guidance on our board of directors. With this funding, we will further expand our availability to deliver expert care as well as launch new brands to treat more of the conditions Americans face.”
Recommended AI News: Sesame Software Announces High-Volume Data Connectors for Oracle Fusion Applications